Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at ...

Carla Harris has been diagnosed with and beaten acute myeloid leukemia thanks to a bone marrow transplant from her sister, ...

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from ...

Study reveals how socioeconomic factors create barriers to bone marrow transplants for AML patients in disadvantaged ...

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...

A 14-year-old Marshfield freshman was surprised earlier today when a special guest visited the Children’s Mercy Hospital, ...